Lead Product(s): Undisclosed
Therapeutic Area: Nutrition and Weight Loss
Highest Development Status: Undisclosed Product Type: Undisclosed
Partner/Sponsor/Collaborator: Boxcar PMJ
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 22, 2020
Proceeds from the financing will be used to accelerate Immuneering’s pipeline including programs in cancer cachexia, next-generation KRAS inhibition and the RAF-MEK pathway.